Incidence and risk factors of trastuzumab-induced cardiac dysfunction in a predominantly Hispanic South Texas population: a descriptive study
Abstract Background Trastuzumab, a monoclonal antibody against human epidermal growth factor receptor 2 (HER2), is often the first line treatment for HER2 positive breast cancer. Although trastuzumab is effective, it has cardiotoxic effects and therefore requires cardiotoxicity monitoring via serial...
Guardat en:
| Autors principals: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMC
2025-02-01
|
| Col·lecció: | Cardio-Oncology |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1186/s40959-025-00319-4 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|